AVIPERO Announces JB1a Reverses Tissue Damage and Induces Tissue Repair in Emphysema
Edinburgh, United Kingdom, November 18, 2011 --(PR.com)-- AVIPERO (Registered in Scotland SC353945) announced today the results of its first R&D therapeutic platform in non-stem cell tissue repair and regeneration.
The principal candidate, JB1a, is an antibody targeting the cell surface adhesion receptor beta1 integrin.
The preclinical study, funded by the Chief Scientist Office for Scotland, describes a novel therapeutic strategy which reverses tissue damage in emphysema. It was demonstrated that targeting beta1 integrin using JB1a shows potent reversal as well as protective effects in a number of in vitro and in vivo models of tissue damage. In an animal model of emphysema, JB1a reversed structural and functional features of emphysema. Emphysema is a major component of a progressive lung disease known as Chronic Obstructive Pulmonary Disease (COPD) characterised by the destruction of tissue around the smaller lung sacs, called alveoli, making these air sacs unable to hold their functional shape upon exhalation and leading to disabling shortness of breath.
The study results were published this month in the online edition of the international peer-reviewed journal Advances in Pharmacological Sciences under the title: “Allosteric modulation of beta1 integrin function induces lung tissue repair.” http://www.hindawi.com/journals/aps/aip/768720 .
Prof. Robert Naylor, AVIPERO’s Director, said this data provides a new paradigm for therapeutics in tissue repair and JB1a is an important early-stage compound. “AVIPERO’s technology platform of tissue repair biologicals show broad repair and protective effects in a variety of diseases and conditions,” explains Prof. Naylor. “JB1a has shown some interesting early-stage results in areas outside of emphysema, for example, arthritis, neurodegeneration and general age-related cellular decline. Such breadth will enable AVIPERO to expand its therapeutic platform and enhance its product pipeline. As the average life span is increasing, it is important to focus on addressing the unmet need of ageing-associated diseases.”
Rehab AlJamal-Naylor, AVIPERO’s Chief Scientific Officer, founder and inventor on the research project said JB1a was chosen for this research because of its broad and profound cellular protective and repair properties demonstrated previously in numerous models of diseases and tissue from human volunteers.
“The generic feature in all the models tested was the increase in mechanical stiffness of the cell that occurs during tissue damage leading to progressive cell death and degeneration. JB1a can reverse functional and structural outcomes through a mechanism involving the mechanical 're-tuning' and allowing normal repair to progress more efficiently,” AlJamal-Naylor said.
In the study, mice suffering from emphysema were treated with JB1a once or twice over a 2-week period. At the end of the treatment period, these mice and various control groups were tested for respiratory function, and structure. The JB1a treated mice showed almost complete reversal of loss of lung elasticity, a measure of lung function. The lung pathology was examined for physical evidence of emphysema. JB1a treatment resulted in a reduction in air space enlargement close to normal.
“We are delighted to see the effect of JB1a in these experiments,” Prof. Naylor said. “These promising results show that JB1a, albeit at a very early stage of development, can provide a potential treatment for emphysema.”
About AVIPERO Ltd.
The principal candidate, JB1a, is an antibody targeting the cell surface adhesion receptor beta1 integrin.
The preclinical study, funded by the Chief Scientist Office for Scotland, describes a novel therapeutic strategy which reverses tissue damage in emphysema. It was demonstrated that targeting beta1 integrin using JB1a shows potent reversal as well as protective effects in a number of in vitro and in vivo models of tissue damage. In an animal model of emphysema, JB1a reversed structural and functional features of emphysema. Emphysema is a major component of a progressive lung disease known as Chronic Obstructive Pulmonary Disease (COPD) characterised by the destruction of tissue around the smaller lung sacs, called alveoli, making these air sacs unable to hold their functional shape upon exhalation and leading to disabling shortness of breath.
The study results were published this month in the online edition of the international peer-reviewed journal Advances in Pharmacological Sciences under the title: “Allosteric modulation of beta1 integrin function induces lung tissue repair.” http://www.hindawi.com/journals/aps/aip/768720 .
Prof. Robert Naylor, AVIPERO’s Director, said this data provides a new paradigm for therapeutics in tissue repair and JB1a is an important early-stage compound. “AVIPERO’s technology platform of tissue repair biologicals show broad repair and protective effects in a variety of diseases and conditions,” explains Prof. Naylor. “JB1a has shown some interesting early-stage results in areas outside of emphysema, for example, arthritis, neurodegeneration and general age-related cellular decline. Such breadth will enable AVIPERO to expand its therapeutic platform and enhance its product pipeline. As the average life span is increasing, it is important to focus on addressing the unmet need of ageing-associated diseases.”
Rehab AlJamal-Naylor, AVIPERO’s Chief Scientific Officer, founder and inventor on the research project said JB1a was chosen for this research because of its broad and profound cellular protective and repair properties demonstrated previously in numerous models of diseases and tissue from human volunteers.
“The generic feature in all the models tested was the increase in mechanical stiffness of the cell that occurs during tissue damage leading to progressive cell death and degeneration. JB1a can reverse functional and structural outcomes through a mechanism involving the mechanical 're-tuning' and allowing normal repair to progress more efficiently,” AlJamal-Naylor said.
In the study, mice suffering from emphysema were treated with JB1a once or twice over a 2-week period. At the end of the treatment period, these mice and various control groups were tested for respiratory function, and structure. The JB1a treated mice showed almost complete reversal of loss of lung elasticity, a measure of lung function. The lung pathology was examined for physical evidence of emphysema. JB1a treatment resulted in a reduction in air space enlargement close to normal.
“We are delighted to see the effect of JB1a in these experiments,” Prof. Naylor said. “These promising results show that JB1a, albeit at a very early stage of development, can provide a potential treatment for emphysema.”
About AVIPERO Ltd.
AVIPERO Ltd (Registered in Scotland SC353945) is a private biopharmaceutical company established in 2009. Avipero is focused on the development of novel therapeutics for unmet clinical needs, characterised by a loss of cells and tissues. This includes conditions such as Parkinson’s disease (PD), chronic obstructive pulmonary disease (COPD), arthritis and age related cell decline. AVIPERO has a proprietary first-in-class therapeutic platform covered by a strong intellectual property portfolio.
About beta1 integrin
Integrins are membrane spanning proteins facilitating the two way communication between the inside and outside of a cell. Integrins have the capacity to bind a multitude of molecules both inside and outside of the cell. The binding of these molecules results in the transmission of information into and out of the cell, which can influence a host of different cellular functions, including the cells metabolic activity and energy.
Of the many types of integrin receptors, the beta1 integrin is by far the most ubiquitous allowing cells to detect a vast array of stimuli ranging from toxins, protein hormones, neurotransmitters and macromolecules. There have been numerous publications documenting a potential role of beta1 integrin in tissue development and repair in several tissue types. It is clear that beta1 integrin plays a crucial role during postnatal skin development and wound healing, with the loss of epithelial beta1 integrin causing extensive skin blistering and wound healing defects.
About COPD
COPD includes a spectrum of disease that encompasses chronic bronchitis and emphysema, a pair of commonly co-existing diseases of the lung in which the airways become narrowed. The narrowing leads to a limitation of the air flow to and from the lungs causing a shortness of breath. In contrast to asthma, the limitation of airflow is poorly reversible and usually gets progressively worse over time. In both bronchitis and emphysema there is localized lung tissue damage with inflammatory cell infiltration resulting in scarring an increasing thickness of the airway walls. COPD is a progressive illness and can lead to death. The incidence of COPD varies. In the UK there are an estimated 850,000 people with COPD or 1 person in 59 receiving a diagnosis of COPD in their lifetime. In the US the prevalence is higher with an estimated 1 in 20 people being diagnosed, or 5% of the population equating to around 13.5 million people. The WHO estimate that in 2005 around 5% (3 million) of all deaths globally where due to COPD, this is set to increase by around 30% over the next 10 years.
Treatment options are limited and address only the symptoms and not the underlying disease. The mainstay treatments are those primarily used to treat asthma and include the short and long acting bronchodilators and the inhaled anti-inflammatory steroids. More recently a number of anticholinergic drugs and PDE4 inhibitors have found favour in treatment of symptoms. However, their safety track record remains to be established.
For Further Information Please Contact:
Robert J. Naylor
AVIPERO Ltd
Director,
07919-621-733
info@avipero.com
I smoked for 23 years, in June 2014 i was diagnosed of Emphysema, i constantly go out of breath and lost my Job in 2015 due to this condition, this continued till a friend of mine told me about Ejiro Herbal Home, according to her she bought Glaucoma herbal medicine from Ejiro Herbal Home that totally cured her mother, so i decided to give it a try too. I was given Dr Ejiro's mobile number and i called him and explained my condition, he recommended a COPD herbal remedy which he said its 100% guaranteed to cure me. I bought this herbal remedy and received it in less than 2 weeks, It was 3 weeks program, i used it as prescribed and was surprised how i gradually gained back my health like the herbal medicine was some sort of magical medicine. All thanks to Ejiro herbal home, contact Ejiro Herbal Home via their website or email ejiroherbalcure@gmail.com or call +27617403481
ReplyDeleteAfter having a persistent cough for over a year, I was diagnosed with COPD
Deletein March 2015. In 2016 my COPD got worse to the point where not only do I
have trouble sleeping at night, I also struggle to get air into my lungs. I
read in a health forum of a herbal centre (native health clinic) who have successful treatment to COPD/Emphysema, i immediately
contacted the herbal centre via their website and purchased the COPD herbal
remedy, I used the remedy for 2 weeks, all my symptoms were reversed, i did
another test for confirmation, i was declared COPD free. email (
nativehealthclinic@gmail.com) or WhatsApp/Call him on +2348140073965
I had COPD for 9 years. My first symptoms were dry cough, chest tightness and shortness of breath. My first chest x-ray only showed bronchitis. Finally I went to a pulmonologist and was diagnosed with COPD.i have used all the medication yet they don’t work, last year December I was told by a formal emphysema patient to use totalcureherbalfoundation@gmail.com herbal treatment which I really did,i was surprise the herbal products effectively get rid of my COPD totally. When you get where you cannot breathe it may be too late. Good luck to each and every one that will be trying their herbal treatment .
ReplyDeleteI'm 59 years old and female. I was diagnosed a couple of months ago with COPD and I was beyond scared! My lung function test indicated 49% capacity. After having had flu a year ago, the shortness of breath, coughing and chest pains continued even after being treated with antibiotics. I've been smoking two packs a day for 36 years. Being born without a sternum caused my ribs to be curled in just one inch away from my spine, resulting to underdeveloped lungs. At age 34 I had surgery and it was fixed. Unfortunately my smoking just caused more damage to my already under developed lungs. The problem was having is that I enjoy smoking and don't want to give up! Have tried twice before and nearly went crazy and don't want to go through that again. I saw the fear in my husband and children's eyes when I told them about my condition then they start to find solution on their own to help my condition.I am an 59 now with moderately severe COPD emphysema which I know was from my years of smoking. I started smoking as a teen in high school when smoking was socially acceptable. I remember when smoking was permitted in hospitals. It was not known then how dangerous cigarettes were for us, and it seemed everybody smoked, i was able to get rid of my COPD lung condition through the help of total cure herbal foundation my husband bought, totalcureherbsfoundation .c om has the right herbal formula to help you get rid and repair any lung conditions and cure you totally. I wish anybody who starts smoking at a young age would realize what will eventually happen to their bodies if they continue that vile habit throughout their lives.
ReplyDelete